AnaptysBio, Inc.
NASDAQ:ANAB
Overview | Financials
Company Name | AnaptysBio, Inc. |
Symbol | ANAB |
Currency | USD |
Price | 14.36 |
Market Cap | 436,956,132 |
Dividend Yield | 0% |
52-week-range | 12.51 - 41.308 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Daniel R. Faga |
Website | https://www.anaptysbio.com |
An error occurred while fetching data.
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD